Elsässer-Beile U[Author] - Search Results

Year	Number of Results
1978	1
1979	1
1981	1
1987	3
1989	1
1991	2
1992	2
1993	5
1994	2
1995	1
1996	3
1998	3
1999	1
2000	5
2001	1
2003	2
2005	2
2006	2
2007	1
2008	3
2009	6
2010	7
2011	2
2012	2
2013	2
2014	1
2015	1
2021	0

1

Bispecific antibodies and diabodies for cancer immunotherapy.

Elsässer-Beile U, Bühler P. Elsässer-Beile U, et al. Immunotherapy. 2012 May;4(5):459-60. doi: 10.2217/imt.12.18. Immunotherapy. 2012. PMID: 22642325 No abstract available.

2

Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates.

Liu J, Kopečková P, Pan H, Sima M, Bühler P, Wolf P, Elsässer-Beile U, Kopeček J. Liu J, et al. Among authors: elsasser beile u. Macromol Biosci. 2012 Mar;12(3):412-22. doi: 10.1002/mabi.201100340. Macromol Biosci. 2012. PMID: 22493797 Free PMC article.

3

Cytokines as therapeutic and diagnostic agents.

Elsässer-Beile U, von Kleist S. Elsässer-Beile U, et al. Tumour Biol. 1993;14(2):69-94. doi: 10.1159/000217827. Tumour Biol. 1993. PMID: 8327838 Review.

4

Targeting the prostate-specific membrane antigen for prostate cancer therapy.

Bühler P, Wolf P, Elsässer-Beile U. Bühler P, et al. Among authors: elsasser beile u. Immunotherapy. 2009 May;1(3):471-81. doi: 10.2217/imt.09.17. Immunotherapy. 2009. PMID: 20635963 Review.

5

Pseudomonas exotoxin A: from virulence factor to anti-cancer agent.

Wolf P, Elsässer-Beile U. Wolf P, et al. Among authors: elsasser beile u. Int J Med Microbiol. 2009 Mar;299(3):161-76. doi: 10.1016/j.ijmm.2008.08.003. Epub 2008 Oct 23. Int J Med Microbiol. 2009. PMID: 18948059 Review.

6

Targeted therapies for prostate cancer against the prostate specific membrane antigen.

Elsässer-Beile U, Bühler P, Wolf P. Elsässer-Beile U, et al. Curr Drug Targets. 2009 Feb;10(2):118-25. doi: 10.2174/138945009787354601. Curr Drug Targets. 2009. PMID: 19199907 Review.

7

Non-invasive in vivo imaging of tumor-associated CD133/prominin.

Tsurumi C, Esser N, Firat E, Gaedicke S, Follo M, Behe M, Elsässer-Beile U, Grosu AL, Graeser R, Niedermann G. Tsurumi C, et al. Among authors: elsasser beile u. PLoS One. 2010 Dec 20;5(12):e15605. doi: 10.1371/journal.pone.0015605. PLoS One. 2010. PMID: 21187924 Free PMC article.

8

Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cells.

Baum V, Bühler P, Gierschner D, Herchenbach D, Fiala GJ, Schamel WW, Wolf P, Elsässer-Beile U. Baum V, et al. Among authors: elsasser beile u. Immunotherapy. 2013 Jan;5(1):27-38. doi: 10.2217/imt.12.136. Immunotherapy. 2013. PMID: 23256796

9

Activation of RhoA,B,C by Yersinia Cytotoxic Necrotizing Factor (CNFy) induces apoptosis in LNCaP prostate cancer cells.

Augspach A, List JH, Wolf P, Bielek H, Schwan C, Elsässer-Beile U, Aktories K, Schmidt G. Augspach A, et al. Among authors: elsasser beile u. Toxins (Basel). 2013 Nov 21;5(11):2241-57. doi: 10.3390/toxins5112241. Toxins (Basel). 2013. PMID: 24284827 Free PMC article.

10

Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody.

Wiehr S, Bühler P, Gierschner D, Wolf P, Rolle AM, Kesenheimer C, Pichler BJ, Elsässer-Beile U. Wiehr S, et al. Among authors: elsasser beile u. Prostate. 2014 May;74(7):743-55. doi: 10.1002/pros.22794. Epub 2014 Mar 9. Prostate. 2014. PMID: 24610028

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results